Viela Bio

Biotech & Life Sciences · Gaithersburg, United States · Founded 2018 · IPO 2019

Viela Bio is focused on developing and commercializing innovative medicines aimed at treating a broad spectrum of autoimmune and severe inflammatory diseases. The company employs a unique approach that targets the underlying molecular causes of these diseases, enabling the development of more precise therapies. This method also helps in identifying patients who are more likely to respond to the treatments and allows for the pursuit of multiple indications for each product candidate. Viela Bio serves patients suffering from autoimmune and severe inflammatory conditions, operating primarily in the biopharmaceutical market. The business model revolves around the research, development, and commercialization of novel therapeutic solutions. Revenue is generated through the sale of these specialized medicines, as well as potential partnerships and licensing agreements with other pharmaceutical companies. Viela Bio's clinical pipeline is robust, with multiple candidates in various stages of development, aimed at addressing unmet medical needs in the autoimmune and inflammatory disease space. Keywords: autoimmune, inflammatory, molecular pathogenesis, precise therapies, biopharmaceutical, clinical pipeline, novel medicines, patient identification, therapeutic solutions, commercialization.

Valuation $3.05B

Revenue $12M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

10 investors on Viela Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 9 investors entered at this stage

Temasek

Boyu Capital

Hillhouse Capital

6 Dimensions Capital

Sirona Capital

HBM Healthcare Investments

Cormorant Asset Management

Goldman Sachs

Viking Global Investors

Series B+ 1 investor entered at this stage

MedImmune

Global footprint

Where Viela Bio has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States83.3%

🇮🇳 India16.7%

2 countries shown

Talent graph

The shape of Viela Bio's talent

Dealroom maps Viela Bio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 team members profilednamed & role-tagged by Dealroom

6 employeestotal headcount

1 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Viela Bio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$49M patent portfolio · 28 active families

Estimated portfolio value

$49M

1.6% of market cap · 1.7× smaller than top peer Innovent Biologics ($84M)

28 active patent families

Where Viela Bio innovates Anti antibodyAntiendomysial antibodiesAutoimmune conditionAutoimmune diseaseBiochemistry

Where Viela Bio concentrates vs peers

Each axis is a top-10 topic across Viela Bio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Viela Bio

An AI-synthesized read of the highest-engagement posts about Viela Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viela Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles